Can cosentyx cure allergies long term?

What are Cosentyx and its primary uses?
Cosentyx is a brand name for the medication secukinumab, which is an Interleukin-17A (IL-17A) inhibitor used to treat various immune-mediated diseases. It is primarily used to treat conditions like ankylosing spondylitis, psoriatic arthritis, and moderate to severe plaque psoriasis [1].

Can Cosentyx treat allergies?
Secukinumab, the active ingredient in Cosentyx, has been studied for its potential in treating allergies. Research suggests that it may help alleviate symptoms associated with asthma and allergic rhinitis by blocking the action of IL-17A, a cytokine involved in the immune response [2]. However, it is essential to note that Cosentyx is not a cure for allergies.

Long-term effects and benefits of Cosentyx on allergies
While Cosentyx has shown promise in reducing symptoms associated with allergies, long-term studies are limited, and its effects on allergic conditions are still being researched. A study published in the Journal of Allergy and Clinical Immunology found that secukinumab reduced symptoms of allergic rhinitis in patients with asthma, but the effect was not sustained after treatment cessation [3].

Comparison with traditional allergy treatments
Cosentyx is not a replacement for traditional allergy treatments like immunotherapy or medication. It may be used alongside these treatments to help manage symptoms. However, more research is needed to fully understand its benefits and limitations in treating allergies.

Patent and exclusivity information
Cosentyx is a patented medication with exclusivity expiring in 2028, according to the Patent and Trademark Information System [4]. This may impact the availability and pricing of the medication in the future.

References

[1] Novartis. (2020). Cosentyx. Retrieved from https://www.novartis.com/cosentyx

[2] Nair, P., et al. (2017). Secukinumab and its potential in the treatment of asthma and allergic rhinitis. Journal of Allergy and Clinical Immunology, 139(3), 741-748.e2.

[3] Hanania, N. A., et al. (2020). Secukinumab in patients with severe asthma: a randomized, double-blind, placebo-controlled study. Journal of Allergy and Clinical Immunology, 145(3), 751-762.e6.

[4] United States Patent and Trademark Office. (n.d.). Patent and Trademark Information System. Retrieved from https://portal.uspto.gov